Naperville, IL -- (SBWire) -- 07/23/2013 --Reportstack, provider of premium market research reports announces the addition of Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022 market report to its offering
Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022
Summary
The publisher has released its new PharmaPoint Drug Evaluation report, Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022. Dermatophytic onychomycosis (DO) is characterized as being a fungal infection of the nail. Infection can involve the nail unit (nail matrix, nail bed, or nail plate). DO isnt considered life-threatening, however can cause patients to experience discomfort, pain, and may cause physical and occupational limitations. DO patients can be identified as having thick or brittle nails along with discoloration (white and opaque). Physicians currently use direct microscopy and fungal culture tests to ensure correct diagnosis and treatment are achieved. Risk factors such as advanced age, pre-existing diabetes, or immunocompromised systems can increase the incidence of DO in patients. Current therapies consist of generics that offer substantial efficacy but sub-par safety profiles. A new wave of therapies is expected to offer topical options for patients who are unable to withstand existing generic options. These therapies are also expected to drive an increase in total drug treatment rates in the US market.
Tavaborole, which was discovered and developed by Anacor Pharmaceuticals, is a topical antifungal from a novel class of antifungal agents known as benzoxaboroles that are being developed for the treatment of DO. Unlike the currently marketed therapies, Anacors tavaborole works by inhibiting a fungal enzyme, leucyl transfer RNA synthetase (LeuRS), which is required for fungal protein synthesis. The inhibition of protein synthesis terminates cell growth and promotes cell death, thereby eliminating the infection. Anacors proprietary boron-based product platform has also been used in developing a second product, AN-2718, which the company has stated will be used in the life-cycle management of its primary drug, tavaborole. Tavaborole has much higher bioavailability and efficacy than ciclopirox, the sole topical agent approved in the US market, because of increased nail penetration at almost 250-fold higher values.
Scope
- Overview of Dermatophytic Onychomycosis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Tavaborole including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Tavaborole for the US from 2012 to 2022.
- Sales information covered for the US
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Dermatophytic Onychomycosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Tavaborole performance
- Obtain sales forecast for Tavaborole from 2012 to 2022 in the US
To view the table of contents for this market research report please visit
http://www.reportstack.com/product/127716/tavaborole-dermatophytic-onychomycosis-forecast-and-market-analysis-to-2022.html
Contact:
Ana Viste
contactus@reportstack.com
Naperville
Illinois
United States
Ph: 888-789-6604
###
Tavaborole (Dermatophytic Onychomycosis) - Forecast and Market Analysis to 2022